Evidence supporting the use of: Resveratrol analogue
For the health condition: Parkinson's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Resveratrol analogues have been investigated in preclinical models for their potential neuroprotective effects in Parkinson’s Disease (PD). The interest is primarily rooted in the well-characterized antioxidant, anti-inflammatory, and mitochondrial protective properties of resveratrol and its structurally similar analogues. Several in vitro and animal studies suggest that resveratrol analogues can attenuate dopaminergic neuronal loss, reduce oxidative stress, and modulate neuroinflammation—hallmarks of PD pathology. For example, studies using MPTP or 6-OHDA-induced PD models in mice and rats demonstrate that resveratrol analogues may improve motor function and protect against neuronal degeneration via the activation of pathways such as SIRT1 and Nrf2. However, there is currently no robust clinical evidence from randomized controlled trials supporting the use of resveratrol analogues for PD in humans. Most data are limited to laboratory and animal research, and issues such as bioavailability and dosing remain unresolved. As such, while there is a scientific rationale and promising preclinical evidence, clinical validation is lacking. Resveratrol analogues are not standard or widely endorsed treatments for PD, and their use is not based on historical or traditional medicine practices. The evidence is therefore rated as 2, indicating promising laboratory research but insufficient human data.

More about Resveratrol analogue
More about Parkinson's Disease

Products containing Resveratrol analogue

We currently have no products on Vitabase that contain this ingredient.